Ruboxistaurin是一种口服有效的蛋白激酶C(PKC)抑制剂，对PKCα、PKCβI和PKCβII的IC50值分别为0.36µM、0.0047µM和0.0059µM。
Cas No.:169939-94-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ruboxistaurin is an orally available inhibitor of protein kinase C (PKC), with IC50 values of 0.36µM, 0.0047µM, and 0.0059µM for PKCα, βI, and βII, respectively[1]. Ruboxistaurin can reduce the adhesion of macrophages to endothelial cells by lowering the expression of inflammatory cytokines and enhancing the antioxidant stress capacity of cells[2]. Ruboxistaurin has been widely used to reduce the degree of glomerular sclerosis and tubulointerstitial fibrosis in mice with kidney removal, and to improve renal function[3].
In vitro, Ruboxistaurin treatment for 24 hours significantly induced cell death in MOLM13 cells and MV4-11 cells, with IC50 values of 0.7µM and 1.5µM, respectively[4]. Treatment with 1µM Ruboxistaurin for 48 hours significantly inhibited VEGF-induced proliferation of human umbilical vein endothelial cells (HUVECs) and phosphorylation of ERK1/2 and Akt[5]. Treatment with 1µM Ruboxistaurin for 6 days inhibited the overall size of the podosome actin belts in mouse bone marrow-derived macrophages (BMMs) induced by RANKL, resulting in a significant reduction in osteoclast formation[2].
In vivo, Ruboxistaurin treatment via oral administration at a dose of 10mg/kg/day for 6 weeks significantly reduced the mRNA expressions of TGF-β1, Smad2, and Smad3 in the kidneys of diabetic rats, and alleviated diabetic nephropathy[6]. Oral administration of Ruboxistaurin (0.5mg/kg) twice daily for 12 weeks effectively inhibited pre-retinal and optic nerve head neovascularization in the pig model of branch retinal vein occlusion[7].
References:
[1] Jirousek M R, Gillig J R, Gonzalez C M, et al. (S)-13-[(Dimethylamino) methyl]-10, 11, 14, 15-tetrahydro-4, 9: 16, 21-dimetheno-1 H, 13 H-dibenzo [e, k] pyrrolo [3, 4-h][1, 4, 13] oxadiazacyclohexadecene-1, 3 (2 H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase Cβ[J]. Journal of medicinal chemistry, 1996, 39(14): 2664-2671.
[2] Pang C, Wen L, Lu X, et al. Ruboxistaurin maintains the bone mass of subchondral bone for blunting osteoarthritis progression by inhibition of osteoclastogenesis and bone resorption activity[J]. Biomedicine & Pharmacotherapy, 2020, 131: 110650.
[3] Kelly D J, Edgley A J, Zhang Y, et al. Protein kinase C-β inhibition attenuates the progression of nephropathy in non-diabetic kidney disease[J]. Nephrology Dialysis Transplantation, 2009, 24(6): 1782-1790.
[4] Fedorov O, Marsden B, Pogacic V, et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases[J]. Proceedings of the National Academy of Sciences, 2007, 104(51): 20523-20528.
[5] Nakamura S, Chikaraishi Y, Tsuruma K, et al. Ruboxistaurin, a PKCβ inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt[J]. Experimental eye research, 2010, 90(1): 137-145.
[6] Al-Onazi A S, Al-Rasheed N M, Attia H A, et al. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways[J]. Journal of Pharmacy and Pharmacology, 2016, 68(2): 219-232.
[7] Danis R P, Bingaman D P, Jirousek M, et al. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531[J]. Investigative ophthalmology & visual science, 1998, 39(1): 171-179.
Ruboxistaurin是一种口服有效的蛋白激酶C(PKC)抑制剂，对PKCα、PKCβI和PKCβII的IC50值分别为0.36µM、0.0047µM和0.0059µM [1]。Ruboxistaurin可通过降低炎症细胞因子的表达和增强细胞的抗氧化应激能力，减少巨噬细胞与内皮细胞的粘附[2]。Ruboxistaurin已被广泛用于减轻肾切除小鼠的肾小球硬化程度和肾小管间质纤维化，并改善肾功能[3]。
在体外，Ruboxistaurin处理24小时显著诱导了MOLM13细胞和MV4-11细胞的死亡，IC50值分别为0.7µM和1.5µM[4]。使用1µM的Ruboxistaurin处理人脐静脉内皮细胞(HUVECs)48小时，显著抑制了VEGF诱导的细胞增殖以及ERK1/2和Akt的磷酸化[5]。使用1µM的Ruboxistaurin处理小鼠骨髓来源的巨噬细胞(BMMs)6天，抑制了RANKL诱导的podosome actin环的整体大小，导致破骨细胞形成显著减少[2]。
在体内，每日口服10mg/kg剂量的Ruboxistaurin，连续6周，显著降低了糖尿病大鼠肾脏中TGF-β1、Smad2和Smad3的mRNA表达，并减轻了糖尿病肾病[6]。每日两次口服Ruboxistaurin（0.5mg/kg），连续12周，有效抑制了猪视网膜分支静脉阻塞模型中的视网膜前和视神经头新生血管形成[7]。
| Cell experiment [1]: | |
Cell lines | Human umbilical vein endothelial cells (HUVECs) |
Preparation Method | HUVECs were seeded into 96-well plates at a density of 2000 cells per well at 37°C for 12h, and preincubated in HuMedia-EB2 containing 2% fetal bovine serum (FBS) at 37°C for 6h. The HUVECs were incubated for 48h in fresh medium containing VEGF (10ng/ml), with various concentrations of Ruboxistaurin (0, 0.1, 0.5, 1.0µM), and then incubated for a further 48h in the fresh medium. After incubation, the viable cell numbers were measured. |
Reaction Conditions | 0, 0.1, 0.5, 1.0µM; 48h |
Applications | Ruboxistaurin treatment significantly reduced cell proliferation of HUVECs induced by VEGF in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male farm pigs |
Preparation Method | Male farm pigs (8-10kg) were anesthetized with intramuscular ketamine-HCl (20mg/kg) and xylazine-HCl (2mg/kg). Pupillary dilation was achieved using 1% tropicamide and 2.5% phenylephrine-HCl. Baseline fundus photographs were obtained, including stereo photography of the optic disc, using a fundus camera. After intravenous injection of rose bengal dye (10mg/kg), selected branch retinal veins were treated with an argon laser with green light using a slit-lamp delivery system and a corneal-contact lens. At least 50% of the total venous area of the retina was occluded by treating the large superior branch vein at the first branch point and one of the inferior vessels at the first branch point. Five pigs were given Ruboxistaurin orally with the standard chow at a dose of 0.5mg/kg twice daily for 12 weeks. Intraocular neovascularization in pigs was determined. |
Dosage form | 0.5mg/kg; twice a day for 12 weeks; p.o. |
Applications | Ruboxistaurin treatment inhibited pre-retinal and optic nerve head neovascularization in the pig model of branch retinal vein occlusion. |
References: | |
| Cas No. | 169939-94-0 | SDF | |
| 别名 | LY333531 | ||
| 分子式 | C28H28N4O3 | 分子量 | 468.55 |
| 溶解度 | DMSO : 50 mg/mL (106.71 mM; ultrasonic and warming and heat to 60°C) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1342 mL | 10.6712 mL | 21.3424 mL |
| 5 mM | 426.8 μL | 2.1342 mL | 4.2685 mL |
| 10 mM | 213.4 μL | 1.0671 mL | 2.1342 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet